[go: up one dir, main page]

AR058049A1 - Proteina de la capsida del virus dengue inductora de respuesta protectora y composicion farmaceutica - Google Patents

Proteina de la capsida del virus dengue inductora de respuesta protectora y composicion farmaceutica

Info

Publication number
AR058049A1
AR058049A1 ARP060104044A ARP060104044A AR058049A1 AR 058049 A1 AR058049 A1 AR 058049A1 AR P060104044 A ARP060104044 A AR P060104044A AR P060104044 A ARP060104044 A AR P060104044A AR 058049 A1 AR058049 A1 AR 058049A1
Authority
AR
Argentina
Prior art keywords
capsida
inducting
virus
pharmaceutical composition
protective response
Prior art date
Application number
ARP060104044A
Other languages
English (en)
Inventor
Tirado Maria Guadalupe Guzman
Cruz Lisset Hermida
Abarrategui Carlos Lopez
Vazquez Beatriz De La C Sierra
Ramundo Susana Vazquez
Prado Iris Valdez
Nieto Gerardo Enrique Guillen
Vazquez Laura Lazo
Morales Aida Zulueta
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR058049A1 publication Critical patent/AR058049A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Proteína de la cápsida de los serotipos del virus Dengue capaz de inducir en el receptor una respuesta inmune protectora frente al reto viral, sin inducir el fenomeno de inmunoamplificacion viral dependiente de anticuerpos Las proteínas recombinantes obtenidas son aplicables a la industria farmacéutica en la obtencion de preparados vacunales contra el Dengue
ARP060104044A 2005-09-16 2006-09-15 Proteina de la capsida del virus dengue inductora de respuesta protectora y composicion farmaceutica AR058049A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050168A CU23578A1 (es) 2005-09-16 2005-09-16 Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal

Publications (1)

Publication Number Publication Date
AR058049A1 true AR058049A1 (es) 2008-01-23

Family

ID=40132555

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104044A AR058049A1 (es) 2005-09-16 2006-09-15 Proteina de la capsida del virus dengue inductora de respuesta protectora y composicion farmaceutica

Country Status (17)

Country Link
US (1) US7790173B2 (es)
EP (1) EP1944038B1 (es)
JP (1) JP5657204B2 (es)
KR (2) KR20130100026A (es)
CN (1) CN101304760B (es)
AR (1) AR058049A1 (es)
AU (1) AU2006291863B2 (es)
BR (1) BRPI0616224B8 (es)
CA (1) CA2622827C (es)
CU (1) CU23578A1 (es)
DK (1) DK1944038T3 (es)
ES (1) ES2444691T3 (es)
MY (2) MY149395A (es)
PT (1) PT1944038E (es)
RU (1) RU2008114841A (es)
WO (1) WO2007031034A1 (es)
ZA (1) ZA200802740B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
SG190562A1 (en) * 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
US20110150914A1 (en) * 2008-06-09 2011-06-23 La Jolla Institute For Allergy And Immunology Compositions and methods for dengue virus (dv) treatment and vaccination
AU2010286368B2 (en) 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
EP2723372A4 (en) * 2011-06-24 2015-03-04 Jolla Inst Allergy Immunolog PROTECTION AGAINST DENGUE VIRUS AND PREVENTION AGAINST HEAVY DENGUE ILLNESSES
IN2015DN02893A (es) 2012-10-04 2015-09-11 Univ Leland Stanford Junior
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
US10487120B2 (en) * 2015-02-09 2019-11-26 Academia Sinica Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018169550A1 (en) * 2017-03-17 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time rt-pcr assay for detection of dengue, chikungunya, and zika viruses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
DK0604566T3 (da) * 1991-09-19 2000-04-10 Us Health Kimærisk og/eller vækstbegrænsede flavivirus
CA2224724C (en) * 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
JPH11513890A (ja) 1996-05-10 1999-11-30 シェーリング コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの合成インヒビター
CU22666A1 (es) 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
CU22683A1 (es) 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
EP1003775B1 (en) 1997-08-11 2005-03-16 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
DE69833002T2 (de) * 1997-10-08 2006-08-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Chimärer impfstoff gegen das zeckenenzephalitis virus
DE60042114D1 (de) 1999-04-30 2009-06-10 Craig J Venter Inst Inc Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
CA3114957C (en) * 2001-05-22 2022-02-08 Stephen S. Whitehead Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
US20040213808A1 (en) 2002-12-11 2004-10-28 Michael Lieberman Recombinant vaccine against flavivirus infection
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
WO2005002501A2 (en) 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.

Also Published As

Publication number Publication date
RU2008114841A (ru) 2009-10-27
KR20130100026A (ko) 2013-09-06
JP5657204B2 (ja) 2015-01-21
US20080311157A1 (en) 2008-12-18
CA2622827C (en) 2015-12-15
US7790173B2 (en) 2010-09-07
EP1944038A1 (en) 2008-07-16
BRPI0616224B1 (pt) 2019-01-15
CN101304760A (zh) 2008-11-12
KR20080048068A (ko) 2008-05-30
PT1944038E (pt) 2014-02-21
MY149395A (en) 2013-08-30
BRPI0616224B8 (pt) 2021-05-25
BRPI0616224A2 (pt) 2013-02-19
KR101350318B1 (ko) 2014-01-14
CA2622827A1 (en) 2007-03-22
AU2006291863A1 (en) 2007-03-22
ES2444691T3 (es) 2014-02-26
EP1944038B1 (en) 2013-11-27
JP2009507864A (ja) 2009-02-26
ZA200802740B (en) 2008-12-31
DK1944038T3 (en) 2014-03-03
CN101304760B (zh) 2013-03-13
AU2006291863B2 (en) 2012-09-20
MY161452A (en) 2017-04-14
CU23578A1 (es) 2010-09-30
WO2007031034A1 (es) 2007-03-22

Similar Documents

Publication Publication Date Title
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
AR058049A1 (es) Proteina de la capsida del virus dengue inductora de respuesta protectora y composicion farmaceutica
WO2010111687A3 (en) Methods and compositions for immunization against virus
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
DK1968632T3 (da) Forbedret influenzavaccine
WO2008103380A3 (en) Hepatitis b virus compositions and methods of use
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
MX340880B (es) Vacunas mejoradas y metodos para uso de las mismas.
EA201892735A1 (ru) Состав вакцины против hiv
AR061894A1 (es) Vacunas para malaria
IN2012DN02692A (es)
AR101814A1 (es) Partícula de tipo virus flavivirus
Cheng et al. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
MX2017014417A (es) Vacunas contra el dengue.
AR095425A1 (es) Vacuna, uso y procedimiento para prevenir una infección por picornavirus
NZ751943A (en) Hepatitis c virus immunogenic compositions and methods of use thereof
HRP20100473T1 (hr) Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c
Chuong et al. Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines
BR112014019755A2 (pt) partícula do tipo viral; método de produção das partículas do tipo viral em uma célula vegetal, um vegetal ou uma parte de um vegetal; composição imunogênica; método de indução de uma resposta imune protetora a um patógeno em um indivíduo; célula vegetal recombinante; e vegetal ou uma parte deste
UY31574A1 (es) Vacunas contra la malaria
AR133824A1 (es) Proteínas virales y nanoestructuras y usos de estas
AR045815A1 (es) Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano

Legal Events

Date Code Title Description
FC Refusal